The Zinc-Binding Group Effect: Lessons from Non-Hydroxamic Acid Vorinostat Analogs

Area of Science:

• Medicinal Chemistry
• Pharmacology
• Biochemistry

Background:

• Histone deacetylases (HDACs) are key drug targets for cancers, inflammation, and neurodegenerative diseases.
• Hydroxamic acid-based HDAC inhibitors (HDACi) face safety concerns, driving research into alternative zinc-binding groups (ZBGs).
• Vorinostat (suberoylanilide hydroxamic acid) is a clinically approved HDACi and a benchmark for ZBG comparison.

Purpose of the Study:

• To provide an overview of non-hydroxamic acid ZBGs used in HDAC inhibitors.
• To enable direct comparison of inhibition potential and biological effects of various ZBGs.
• To discuss strategies for ZBG selection, their properties, activity, and liabilities.

Main Methods:

• Review and analysis of non-hydroxamic acid ZBGs incorporated into vorinostat analogs.
• Comparative assessment of different ZBGs based on published data.
• Discussion of ZBG selection strategies and their impact on inhibitor profiles.

Main Results:

• Identified and categorized various non-hydroxamic acid ZBGs for HDAC inhibition.
• Demonstrated how ZBG modifications influence HDAC inhibitor potency and selectivity.
• Highlighted the trade-offs between different ZBGs regarding activity and potential liabilities.

Conclusions:

• Non-hydroxamic acid ZBGs offer a promising avenue for developing safer and more effective HDAC inhibitors.
• Direct comparison of ZBGs within a similar chemical scaffold (vorinostat analogs) is crucial for understanding structure-activity relationships.
• Further research into novel ZBGs is warranted to overcome the limitations of current HDACi therapies.